Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,445 stopped studies mapped to Lymphoid Neoplasm and descendants · 89% state a reason
Over the 1,445 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00984828 | Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in… | Phase 2 / Phase 3 | terminated | Sep 25, 2009 | Shanghai Jiao Tong University School of Medicine | Very slow recruitment | Enrollment / accrual |
| NCT02808091 | Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T…(Gifox-B) | Phase 2 | terminated | Jun 21, 2016 | National Cancer Centre, Singapore | Slow recruitment | Enrollment / accrual |
| NCT02230917 | A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple… | Phase 2 | withdrawn | Sep 3, 2014 | Rebecca Silbermann | not stated | Not stated |
| NCT00879528 | Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in… | — | terminated | Apr 10, 2009 | Fondazione Italiana Linfomi - ETS | Failure of accrual achievement | Enrollment / accrual |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Nov 3, 2014 | Mayo Clinic | not stated | Not stated |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT02640833 | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic… | Phase 1 | withdrawn | Dec 29, 2015 | AbbVie | Study Stopped | Other (stated, no rule matched) |
| NCT01078974 | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia | Phase 1 | terminated | Mar 2, 2010 | Steven P. Treon, MD, PhD | Safety concerns (IgM Flare) | Safety / toxicity |
| NCT01096810 | Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma | Phase 2 | terminated | Mar 31, 2010 | Jagannath, Sundar, M.D. | The research is permanently closed to enrollment. | Enrollment / accrual |
| NCT02739594 | Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma(COMPARE) | Phase 3 | terminated | Apr 15, 2016 | Hoffmann-La Roche | Slow recruitment | Enrollment / accrual |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT02046928 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia… | Phase 2 | terminated | Jan 28, 2014 | Ångstrom Pharmaceuticals | Slow enrollment | Enrollment / accrual |
| NCT02447055 | Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma | Early Phase 1 | withdrawn | May 18, 2015 | Washington University School of Medicine | not stated | Not stated |
| NCT00983346 | Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients | Phase 2 | terminated | Sep 24, 2009 | University of Utah | Lab Staff that was required left the institution, therefore accrual closed prematurely | Enrollment / accrual |
| NCT01144754 | Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP… | — | terminated | Jun 16, 2010 | Stanford University | Low Accrual | Enrollment / accrual |
| NCT01556828 | Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing | — | terminated | Mar 16, 2012 | Stanford University | not stated | Not stated |
| NCT02273856 | Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic…(NADIR) | — | terminated | Oct 24, 2014 | Astellas Pharma International B.V. | The study was terminated due to insufficient subject enrollment and very slow enrollment. | Enrollment / accrual |
| NCT01536067 | Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom… | Phase 2 | terminated | Feb 20, 2012 | Roswell Park Cancer Institute | funding was withdrawn | Funding |
| NCT02080416 | Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors | Early Phase 1 | terminated | Mar 6, 2014 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Very slow accrual; terminated to allow resources to be utilized more effectively on other studies.… | Enrollment / accrual |
| NCT01658904 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | Phase 1 / Phase 2 | terminated | Aug 7, 2012 | National Cancer Institute (NCI) | study closed prematurely because investigator left National Institutes of Health | Investigator |
| NCT01182233 | Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic… | Phase 1 | terminated | Aug 16, 2010 | University of Rochester | low enrollment | Enrollment / accrual |
| NCT01807286 | Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis | Phase 1 | terminated | Mar 8, 2013 | M.D. Anderson Cancer Center | Sponsor requested termination | Other (stated, no rule matched) |
| NCT02735876 | A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus… | Phase 3 | withdrawn | Apr 13, 2016 | Acerta Pharma BV | not stated | Not stated |
| NCT00892346 | Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line… | Phase 3 | suspended | May 4, 2009 | Shanghai Jiao Tong University School of Medicine | No avaliability of melphlan in mainland China | Other (stated, no rule matched) |
| NCT01501370 | Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in…(ZLd_Ld) | Phase 2 | withdrawn | Dec 29, 2011 | Tiziana Marangon | not stated | Not stated |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | Phase 1 / Phase 2 | terminated | Dec 21, 2007 | Baylor College of Medicine | slow accrual | Enrollment / accrual |
| NCT01016028 | Chemotherapy-Induced Peripheral Neuropathy Survey | — | withdrawn | Nov 18, 2009 | M.D. Anderson Cancer Center | Study assessment tool development delayed. | Other (stated, no rule matched) |
| NCT00578461 | T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE(REGKINE) | N/A | terminated | Dec 21, 2007 | Baylor College of Medicine | not stated | Not stated |
| NCT00578539 | T-Reg Cell Kinetics, Stem Cell Transplant, REGALE(REGALE) | N/A | terminated | Dec 21, 2007 | Baylor College of Medicine | not stated | Not stated |
| NCT00142168 | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Sep 2, 2005 | Dana-Farber Cancer Institute | Toxicity | Safety / toxicity |
| NCT01578343 | Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma(ZOLINZA) | Phase 2 | terminated | Apr 16, 2012 | Samsung Medical Center | we collected data of a total of 19 patients for an interim analysis. but there are less than 7… | Efficacy / futility |
| NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of… | Phase 1 / Phase 2 | terminated | Dec 2, 2009 | Cephalon | not stated | Not stated |
| NCT02140840 | UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the… | Phase 2 | withdrawn | May 16, 2014 | University of Arkansas | PI left institution | Investigator |
| NCT00615589 | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity… | Phase 2 | terminated | Feb 14, 2008 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT01518153 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | Phase 2 | terminated | Jan 25, 2012 | M.D. Anderson Cancer Center | Objectives not met. | Other (stated, no rule matched) |
| NCT00836173 | Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate,… | Phase 2 | withdrawn | Feb 4, 2009 | Loyola University | Gallium is no longer available for the conduct of this study. | Other (stated, no rule matched) |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Phase 1 | terminated | Apr 23, 2008 | Erimos Pharmaceuticals | Funding constraints | Funding |
| NCT02054559 | R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL(ASPIRE) | Phase 3 | withdrawn | Feb 4, 2014 | Asan Medical Center | No consensus among trial centers regarding protocol | Other (stated, no rule matched) |
| NCT00337259 | Gemcitabine for Marginal Zone Lymphoma | Phase 2 | terminated | Jun 15, 2006 | Asan Medical Center | poor accrual and response less than expected on interim analysis | Efficacy / futility |
| NCT01500538 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma…(VEIL) | Phase 2 | terminated | Dec 28, 2011 | Peter MacCallum Cancer Centre, Australia | Poor recruitment rate | Enrollment / accrual |
| NCT01329289 | SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | Phase 2 | withdrawn | Apr 5, 2011 | University of Pittsburgh | Clinical trial being transferred to Columbia University with the Investigator. | Investigator |
| NCT00310128 | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in… | Phase 2 | withdrawn | Apr 3, 2006 | AIDS Malignancy Consortium | Drug supply unavailable | Drug supply |
| NCT00849524 | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects… | Phase 2 | terminated | Feb 24, 2009 | Januario Castro, M.D. | drug supply became unavailable | Drug supply |
| NCT00942409 | Study of Repeat Intranodal Injections of Ad-ISF35 | Phase 2 | terminated | Jul 20, 2009 | Januario Castro, M.D. | drug supply was no longer available | Drug supply |
| NCT00575965 | Simvastatin in Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Dec 18, 2007 | Dana-Farber Cancer Institute | Slow accrual led to early study termination. | Enrollment / accrual |
| NCT01010568 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Nov 10, 2009 | Georgetown University | Unable to accrue patients due to change in standard CLL therapy | Enrollment / accrual |
| NCT00538187 | Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent… | Phase 1 | terminated | Oct 2, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00512980 | PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma | Phase 2 | terminated | Aug 8, 2007 | University of Cologne | lower recruitment rates as expected | Enrollment / accrual |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | Phase 1 / Phase 2 | terminated | Jun 21, 2012 | Singapore General Hospital | Funding expired | Funding |
| NCT00384150 | Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) | Phase 3 | terminated | Oct 5, 2006 | Biogen | Enrollment challenges due to changes in standards of care resulted in premature termination. No… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 8, 2016source: clinicaltrials